Trial Profile
A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 May 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Trabectedin (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- 29 Mar 2022 Primary endpoint (Objective response rate (ORR) has not been met according to the results published in the Clinical Cancer Research
- 29 Mar 2022 Results published in the Clinical Cancer Research
- 16 Nov 2020 Status changed from active, no longer recruiting to discontinued.